Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Vida J Gorys

Montse Llinas-Brunet

Jean Rancourt

Murray D Bailey

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

Sylvie Goulet

Pasquale Forgione

Punit R Bhardwaj

Josee Bordeleau

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Compounds of formula I: wherein Ris hydroxy or NHSORwherein Ris (C)alkyl, (C)cycloalkyl or {(C)alkyl-(C)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C)alkyl, amido, amino or phenyl, or Ris Cor Caryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C)alkyl, O(C)alkyl, amido, amino or phenyl; Ris (C)cycloalkyl and Ris cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Hepatitis C inhibitor tri-peptides

Growing community of inventors

Dollard-des-Ormeaux, Canada

Vida J Gorys